Trinity Biotech PLC (TRIB)
0.80
+0.03
(+3.90%)
USD |
NASDAQ |
Dec 20, 16:00
0.799
0.00 (0.00%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 22.02M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -68.00% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.1483 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -3.106 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 96.74% |
Profile
| Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment. |
| URL | https://www.trinitybiotech.com |
| Investor Relations URL | http://www.trinitybiotech.com/investor-relations/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Apr. 04, 2025 (est.) |
| Last Earnings Release | Nov. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 05, 2015 |
Ratings
Profile
| Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment. |
| URL | https://www.trinitybiotech.com |
| Investor Relations URL | http://www.trinitybiotech.com/investor-relations/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Apr. 04, 2025 (est.) |
| Last Earnings Release | Nov. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 05, 2015 |